Inhibition of Src reduces gemcitabine-induced cytotoxicity in human pancreatic cancer cell lines

被引：7

作者：

Ichihara, Naoto ^{[1
]}

Kubota, Yoshitsugu ^{[2
]}

Kitanaka, Akira ^{[1
]}

Tanaka, Terukazu ^{[1
]}

Taminato, Tornohiko ^{[1
]}

机构：

[1] Kagawa Univ, Fac Med, Dept Lab Med, Miki, Kagawa 7610793, Japan

[2] Kagawa Univ, Fac Med, Dept Transfus Med, Miki, Kagawa 7610793, Japan

来源：

CANCER LETTERS | 2008年 / 260卷 / 1-2期

关键词：

Src; pancreatic cancer; gemcitabine; PP2;

D O I：

10.1016/j.canlet.2007.10.035

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the present study, we examined the role of Src in gemcitabine-induced cell growth suppression in human pancreatic cancer cell lines. In two human pancreatic cancer cell lines, PK-9 and MIA PaCa-2, we found that a selective Src protein tyrosine kinase inhibitor, PP2, inhibited gemcitabine-induced cell growth suppression. When dominant negative src cDNA was constitutively expressed in PK-9 cells (PK-9-Src-DN), the degree of gemcitabine-induced cell growth suppression was decreased compared with that of mock-transfected PK-9 cells. The mechanism of the inhibitory effect of gemcitabine-induced cytotoxicity was found to be the suppression of apoptosis, which was downregulated in PK-9-Src-DN cells. These results indicate that Src mediates signals that culminate in suppressing cell growth and survival in the presence of gemcitabine, at least in particular cell lines. (C) 2007 Elsevier Ireland Ltd. All rights reserved.

引用

页码：155 / 162

页数：8

共 38 条

[1] New applications of gemcitabine and future directions in the management of pancreatic cancer [J].

Abbruzzese, JL .

CANCER, 2002, 95 (04) :941-945

[2] The role of Src in solid and hematologic malignancies - Development of new-generation Src inhibitors [J].

Alvarez, Ricardo H. ;

Kantarjian, Hagop M. ;

Cortes, Jorge E. .

CANCER, 2006, 107 (08) :1918-1929

[3] Oncogenic kinase signalling [J].

Blume-Jensen, P ;

Hunter, T .

NATURE, 2001, 411 (6835) :355-365

[4]

Boudny V, 2003, ANTICANCER RES, V23, P7

[5] Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2 [J].

Boudny, V ;

Nakano, S .

BRITISH JOURNAL OF CANCER, 2002, 86 (03) :463-469

[6] The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression [J].

Chen, J ;

Röcken, C ;

Nitsche, B ;

Hosius, C ;

Gschaidmeier, H ;

Kahl, S ;

Malfertheiner, P ;

Ebert, MPA .

CANCER LETTERS, 2006, 233 (02) :328-337

[7] THE WHEN AND HOW OF SRC REGULATION [J].

COOPER, JA ;

HOWELL, B .

CELL, 1993, 73 (06) :1051-1054

[8] Aplidin TM induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK [J].

Cuadrado, A ;

García-Fernández, LF ;

González, L ;

Suárez, Y ;

Losada, A ;

Alcaide, V ;

Martínez, T ;

Fernández-Sousa, JM ;

Sánchez-Puelles, JM ;

Muñoz, A .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (01) :241-250

[9] siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity [J].

Duxbury, MS ;

Ito, H ;

Zinner, MJ ;

Ashley, SW ;

Whang, EE .

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 198 (06) :953-959

[10] Inhibition of Src tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells [J].

Duxbury, MS ;

Ito, H ;

Zinner, MJ ;

Ashley, SW ;

Whang, EE .

CLINICAL CANCER RESEARCH, 2004, 10 (07) :2307-2318

← 1 2 3 4 →